An open-label, phased-increasing dose, Phase 1/2a clinical trial to evaluate the safety and efficacy of allogeneic placenta-derived mesenchymal stem cell therapy (PLARTISTEM®) in patients with osteoarthritis
100 Clinical Results associated with Medicrinia
0 Patents (Medical) associated with Medicrinia
100 Deals associated with Medicrinia
100 Translational Medicine associated with Medicrinia